PolyPid (PYPD) director awarded 9,132 stock options at $4.46 strike price
Rhea-AI Filing Summary
PolyPid Ltd. director Joseph BenAmram reported a compensation grant of stock options to acquire 9,132 Ordinary Shares. The options have an exercise price of $4.46 per share and expire on July 15, 2036. They vest on a quarterly basis beginning July 15, 2026 until April 15, 2030, and this award brings his reported stock option holdings to 9,132 options.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
BenAmram Joseph
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) F1 | 9,132 | $4.46 | $41K |
Holdings After Transaction:
Stock option (right to buy) — 9,132 shares (Direct)
Footnotes (1)
- F1. The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030.
Key Figures
Options Granted: 9132.0000 options
Exercise Price: $4.4600 per share
Underlying Shares: 9132.0000 shares
+4 more
7 metrics
Options Granted
9132.0000 options
Stock option grant reported by director on 2026-07-15
Exercise Price
$4.4600 per share
Exercise price for the granted stock options
Underlying Shares
9132.0000 shares
Ordinary Shares underlying the granted stock options
Expiration Date
2036-07-15
Expiration date of the granted stock options
Vesting Start
2026-07-15
Quarterly vesting begins on July 15, 2026
Vesting End
2030-04-15
Quarterly vesting continues until April 15, 2030
Holdings After Grant
9132.0000 options
Total stock options held by the director following this transaction
Key Terms
Stock option (right to buy), exercise price, vesting, Ordinary Shares
4 terms
Stock option (right to buy) financial
"security_title: Stock option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 4.4600"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The options vest on a quarterly basis beginning July 15, 2026"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What transaction did PolyPid (PYPD) director Joseph BenAmram report?
Director Joseph BenAmram reported a grant of stock options in PolyPid Ltd. The award covers 9,132 options to purchase Ordinary Shares at an exercise price of $4.46 per share, expiring on July 15, 2036, as director compensation.
How many PolyPid (PYPD) options were granted to director Joseph BenAmram?
Joseph BenAmram was granted 9,132 stock options in PolyPid. Each option relates to one Ordinary Share, giving rights over 9,132 underlying shares. Following this grant, his reported stock option holdings total 9,132 options with no sales disclosed.
What is the exercise price of the stock options granted to PolyPid (PYPD) director Joseph BenAmram?
The granted options have an exercise price of $4.46 per share. This means each option allows purchase of one PolyPid Ordinary Share at $4.46, regardless of future market price, subject to vesting and the stated expiration date of July 15, 2036.
What is the vesting schedule for Joseph BenAmram’s PolyPid (PYPD) stock options?
The options vest on a quarterly basis, beginning July 15, 2026 and continuing until April 15, 2030. This staged vesting means portions of the 9,132 granted options become exercisable over time rather than all at once.
When do the stock options granted to PolyPid (PYPD) director Joseph BenAmram expire?
The granted stock options carry an expiration date of July 15, 2036. After this date, any unexercised options from the 9,132-option award will lapse. The options vest quarterly between July 15, 2026 and April 15, 2030.
Does the PolyPid (PYPD) Form 4 indicate any stock sales by director Joseph BenAmram?
No stock sales are reported; the filing shows only a grant of 9,132 stock options. The transaction is coded as a grant, award, or other acquisition, increasing his reported option holdings to 9,132 options with no dispositions listed.